A dual role for Mannan-binding lectin-associated serine protease 2 (MASP-2) in HIV infection.

Autor: Boldt AB; Laboratório de Imunopatologia Molecular, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil; Laboratório de Genética Molecular Humana, Universidade Federal do Paraná, Curitiba, Brazil., Beltrame MH; Laboratório de Imunopatologia Molecular, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil., Catarino SJ; Laboratório de Imunopatologia Molecular, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil., Meissner CG; Laboratório de Imunopatologia Molecular, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil., Tizzot R; Laboratório de Imunopatologia Molecular, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil., Messias-Reason IJ; Laboratório de Imunopatologia Molecular, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil. Electronic address: iarareason@hc.ufpr.br.
Jazyk: angličtina
Zdroj: Molecular immunology [Mol Immunol] 2016 Oct; Vol. 78, pp. 48-56. Date of Electronic Publication: 2016 Aug 30.
DOI: 10.1016/j.molimm.2016.08.015
Abstrakt: Background: Mannan-binding lectin (MBL) - associated serine protease 2 (MASP-2) co-activates the lectin pathway of complement in response to several viral infections. The quality of this response partly depends on MASP2 gene polymorphisms, which modulate MASP-2 function and serum levels. In this study we investigated a possible role of MASP2 polymorphisms, MASP-2 serum levels and MBL-mediated complement activation in the susceptibility to HIV/AIDS and HBV/HCV coinfection.
Methods: A total of 178 HIV patients, 89 (50%) coinfected with HBV/HCV, 51.7% female, average age 40 (12-73) years, and 385 controls were evaluated. MASP-2 levels and MBL-driven complement activation were evaluated by enzyme-linked immunosorbent assay and 11 MASP2 polymorphisms from the promoter to the last exon were haplotyped using multiplex sequence-specific PCR.
Results: Genotype distribution was in Hardy-Weinberg equilibrium and differed between HIV+ patients and controls (P=0.030), irrespective of HBV or HCV coinfection. The p.126L variant, which was associated with MASP-2 levels <200ng/mL (OR=5.0 [95%CI=1.3-19.2] P=0.019), increased the susceptibility to HIV infection (OR=5.67 [95%CI=1.75-18.33], P=0.004) and to HIV+HBV+ status (OR=6.44 [95%CI=1.69-24.53, P=0.006). A similar association occurred with the ancient haplotype harboring this variant, AGCDV (OR=2.35 [95%CI=1.31-4.23], P=0.004). On the other hand, p.126L in addition to other variants associated with low MASP-2 levels-p.120G, p.377A and p.439H, presented a protective effect against AIDS (OR=0.25 [95%CI=0.08-0.80], P=0.020), independently of age, sex, hepatic function and viral load. MASP-2 serum levels were lower in HIV+ and HIV+HBV+ patients than in controls (P=0.0004). Among patients, MASP-2 levels were higher in patients with opportunistic diseases (P=0.001) and AIDS (P=0.004). MASP-2 levels correlated positively with MBL/MASP2-mediated C4 deposition (r=0.29, P=0.0002) and negatively with CD4+ cell counts (r=-0.21, P=0.018), being related to decreased CD4+ cell counts (OR=5.8 [95%CI=1.23-27.5, P=0.026).
Conclusions: Genetically determined MASP-2 levels seem to have a two-edge effect in HIV and probably HCV/HBV coinfection, whereas low levels increase the susceptibility to infection, but on the other side protects against AIDS.
(Copyright © 2016 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: